Hybrid imaging systems in the diagnosis of osteomyelitis and prosthetic joint infection

Quarterly Journal of Nuclear Medicine and Molecular Imaging

Volumn 53, Issue 1, 2009, Pages 95-104

  Schillaci, Orazio ^a,b  

^a UNIVERSITY OF ROME TOR VERGATA   (Italy)

^b NONE   (Italy)

Author keywords

Infections; Joint prostheses; Osteomyelitis

Indexed keywords

GALLIUM 67; GRANULOCYTE ANTIBODY; HEXAMETHYLPROPYLENE AMINE OXIME TECHNETIUM TC 99M; IODINATED CONTRAST MEDIUM;

ARTHROPLASTY; BONE SCINTISCANNING; COMPUTER ASSISTED EMISSION TOMOGRAPHY; DIAGNOSTIC ACCURACY; DIAGNOSTIC ERROR; DIAGNOSTIC VALUE; DRUG UPTAKE; EARLY DIAGNOSIS; FALSE POSITIVE RESULT; GRANULOCYTE; HISTOPATHOLOGY; HUMAN; HYPERGLYCEMIA; IMAGE ANALYSIS; IMAGE DISPLAY; IMMUNOSCINTIGRAPHY; INFECTIOUS ARTHRITIS; INTERVERTEBRAL DISK DEGENERATION; JOINT PROSTHESIS; LEUKOCYTE; MONONUCLEAR CELL; MULTIDETECTOR COMPUTED TOMOGRAPHY; NUCLEAR MEDICINE; OSTEOARTHROPATHY; OSTEOMYELITIS; REVIEW; SENSITIVITY AND SPECIFICITY; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY;

ARTHROPLASTY, REPLACEMENT; BONE DISEASES, INFECTIOUS; DIAGNOSTIC IMAGING; HUMANS; OSTEOMYELITIS;

EID: 65749084224     PISSN: 18244785     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (51)

1. Prandini N, Lazzeri E, Rossi B, Erba P, Parisella MG, Signore A. Nuclear medicine imaging of bone infections. Nucl Med Commun 2006;27:633-44.
2. El-Maghraby TA, Moustafa HM, Pauwels EK. Nuclear medicine methods for evaluation of skeletal infection among other diagnostic modalities. Q J Nucl Med Mol Imaging 2006;50:167-92.
3. Wagner HN. Images of the future. J Nucl Med 1978;19:599-605.
4. Bunyaviroch T, Aggarwal A, Oates ME. Optimized scintigraphic evaluation of infection and inflammation: role of single-photon emission computed tomography/computed tomography fusion imaging. Semin Nucl Med 2006;36:295-311.
5. Strobel K, Stumpe KD. PET/CT in musculoskeletal infection. Semin Musculoskelet Radiol 2007;11:353-64.
6. Treves ST, Mitchell KD, Habboush IH. Three-dimensional image alignment, registration and fusion. J Nucl Med 1998; 42:83-92.
7. Coreia JA. Registration of nuclear medicine images. J Nucl Med 1990;31:1227-9.
8. Hutton BF, Braun M, Thurfjell L, Lau DYH. Image registration: an essential tool for nuclear medicine. Eur J Nucl Med Mol Imaging 2002;29:559-77.
9. von Schulthess GK, Pelc NJ. Integrated-modality imaging: the best of both words. Acad Radiol 2002;9:1241-4.
10. Schillaci O, Simonetti G. Fusion imaging in nuclear medicine-applications of dual-modality systems in oncology. Cancer Biother Radiopharm 2004;19:1-10.
11. Townsend DW. Dual-modality imaging: combining anatomy and function. J Nucl Med 2008;49:938-55.
12. Kramer EL, Noz ME. CT-SPECT fusion for analysis of radiolabeled antibodies: applications in gastrointestinal and lung carcinoma. Nucl Med Biol 1991;18:27-42.
13. Bocher M, Balan A, Krausz Y, Shrem Y, Lonn A, Wilk M et al. Gamma camera-mounted anatomical X-ray tomography: technology, system characteristics and first images. Eur J Nucl Med 2000;27:619-27.
14. Delbeke D, Coleman RE, Guiberteau MJ, Brown ML, Royal HD, Siegel BA et al. Procedure guideline for SPECT/CT Imaging 1.0. J Nucl Med 2006;47:1227-34.
15. Schillaci O, Danieli R, Manni C, Simonetti G. Is SPECT/CT with a hybrid camera useful to improve scintigraphic imaging interpretation? Nucl Med Commun 2004;25:705-10.
16. O'Connor MK, Kemp BJ. Single-photon emission computed tomography/ computed tomography: basic instrumentation and innovations. Semin Nucl Med 2006;36:258-66.
17. Seo Y, Mari C, Hasegawa BH. Technological development and advances in single-photon emission computed tomography/computed tomography. Semin Nucl Med 2008;38:177-98.
18. Townsend DW. Positron emission tomography/computed tomography. Semin Nucl Med 2008;38:152-66.
19. McCall MS, Sutherland DA, Eisentraut AM, Lanz H. The tagging of leukemic leukocytes with radioactive chromium and measurement of the in vivo cell survival. J Lab Clin Med 1955;45:717-24.
20. Athens JW, Mauer AM, Ashenbrucker H, Cartwright GE, Wintrobe MM. Leukokinetic studies. I. A method for labeling leukocytes with diisopropyl-fluorophosphate (DFP32). Blood 1959;14:303-33.
21. Horger M, Eschmann SM, Pfannenberg C, Storek D, Dammann F, Vonthein R et al. The value of SPET/CT in chronic osteomyelitis. Fur J Nucl Med Mol Imaging 2003;30:1665-73.
22. Horger M, Eschmann SM, Pfannenberg C, Storek D, Vonthein R, Claussen CD et al. Added value of SPECT/CT in patients suspected of having bone infection: preliminary results. Arch Orthop Trauma Surg 2007;127:211-21.
23. 111In-labeled leukocyte scintigraphy for diagnosis of infection. J Nucl Med 2006; 47:587-94.
24. Weon YC, Yang SO, Choi YY, Shin JW, Ryu JS, Shin MJ et al. Use of Tc-99m-HMPAO leukocyte scans to evaluate bone infection: incremental value of additional SPECT images. Clin Nucl Med 2000;25:519-26.
25. 99mTc-HMPAO-labeled leukocyte scintigraphy for bone and joint infections. J Nucl Med 2006;47:1908-13.
26. Schillaci O. SPECT/CT: a new era for SPECT imaging? Eur J Nucl Med Imaging 2005;32:521-4.
27. von Schulthess GK, Steinert HC, Hany TF. Integrated PET/CT: current applications and future directions. Radiology 2006;238:405-22.
28. Pauwels EK, Ribeiro MJ, Stoot JH, McCready VR, Bourguignon M, Maziere B. FDG accumulation and tumor biology. Nucl Med Biol 1998;25:317-22.
29. Love C, Tomas MB, Tronco GG, Palestro CJ. FDG PET of infection and inflammation. Radiographics 2005;25:1357-68.
30. Zhuang H, Alavi A. 18-fluorodeoxyglucose positron emission tomographic imaging in the detection and monitoring of infection and inflammation. Semin Nucl Med 2002;32:47-59.
31. 18F-FDG uptake in activated monocytes occurs during the priming process and involves tyrosine kinases and protein kinase C. J Nucl Med 2004;45:124-8.
32. Metler J, Sahlmann CO, Liersch T, Hao Tang P, Alavi A. Nonprosthesis orthopedic applications of (18)F fluoro-2-deoxy-D-glucose PET in the detection of osteomyelitis. Radiol Clin North Am 2007;45:719-33.
33. 18F] fluorodeoxyglucose PET. Q J Nucl Med Mol Imaging 2008;52:17-29.
34. 18F FDG-PET imaging in musculoskeletal infection. Q J Nucl Med Mol Imaging 2006;50:131-42.
35. 18F-FDG PET of experimental Stapbylococcus aureus osteomyelitis and normal bone healing. J Nucl Med 2004;45:1406-11.
36. 18F-FDG PET/CT in trauma patients with suspected chronic osteomyelitis. Eur J Nucl Med Mol Imaging 2007; 34:704-14.
37. Lavery LA, Armstrong DG, Wunderlich RP, Mohler MJ, Wendel CS, Lipsky BA. Risk factors for foot infections in individuals with diabetes. Diabetes Care 2006;29:1288-93.
38. Bamberger DM, Daus GP, Gerding DN. Osteomyelitis in the feet of diabetic patients. Long-term results, prognostic factors, and the role of antimicrobial and surgical therapy. Am J Med 1987;83:653-60.
39. Lipsky BA. Osteomyelitis of the foot in diabetic patients. Clin Infect Dis 1997;25:1318-26.
40. Lipsky BA. A report from the international consensus on diagnosing and treating the infected diabetic foot. Diabetes Metab Res Rev 2004;20 Suppl 1:S68-77.
41. 18F-FDG PET/CT. J Nucl Med 2005; 46:444-9.
42. Zhuang HM, Cortes-Blanco A, Pourdehnad M, Adam LE, Yamamoto AJ, Martínez-Lázaro R et al. Do high glucose levels have differential effect on FDG uptake in inflammatory and malignant disorders? Nucl Med Commun 2001;22:1123-8.
43. 18F-labeled fluorodeoxyglucose PET in the management of patients with arthroplasty. Radiol Clin North Am 2007;45:711-8.
44. Kwee TC, Kwee RM, Alavi A. FDG-PET for diagnosing prosthetic joint infection: systematic review and metaanalysis. Eur J Nucl Med Mol Imaging 2008;35:2122-32.
45. Goerres GW, Ziegler SI, Burger C, Berthold T, Von Schulthess GK, Buck A. Artifacts at PET and PET/CT caused by metallic hip prosthetic material. Radiology 2003;226:577-84.
46. Kaneta T, Takanami K, Wakayama Y, Sato A, Higano S, Fukuda H et al. High-density materials do not always induce artifacts on PET/CT: what is responsible for the difference? Nucl Med Commun 2007;28:495-9.
47. 18F-FDG-labeled leukocytes. Q J Nucl Med Mol Imaging 2006; 50:143-6.
48. 18F]fluoro-2-deoxy-D-glucose as a potential in vitro agent for labelling human granulocytes for clinical studies by positron emission tomography. Int J Rad Appl Instrum B 1992;19:183-90.
49. Forstrom LA, Dunn WL, Mullan BP, Hung JC, Lowe VJ, Thorson LM. Biodistribution and dosimetry of [(18)F]fluorodeoxyglucose labelled leukocytes in normal human subjects. Nucl Med Commun 2002;23:721-5.
50. 18F-FDG. J Nucl Med. 2005;46:1522-30.
51. 18F-FDG-labeled leukocyte PET/CT: initial experience in 21 patients. J Nucl Med 2006; 47:625-32.